NRG Oncology BR005: Phase II trial assessing accuracy of tumor bed biopsies (Bx) in predicting pathologic response in patients (Pts) with clinical/radiological complete response (CR) after neoadjuvant chemotherapy (NCT) in order to explore the feasibility of breast-conserving treatment (BCT) without surgery.

Basik, Mark; P. Costantino, Joseph; F. De Los Santos, Jennifer; Umphrey, Heidi; B. Julian, Thomas; P. Mamounas, Eleftherios; White, Julia; C. Lucas, Peter; L. Wagner, Jamie; A. Tjoe, Judy; M. Thompson, Alastair; Wolmark, Norman

doi:10.1200/jco.2018.36.15_suppl.tps604

Public

NRG Oncology BR005: Phase II trial assessing accuracy of tumor bed biopsies (Bx) in predicting pathologic response in patients (Pts) with clinical/radiological complete response (CR) after neoadjuvant chemotherapy (NCT) in order to explore the feasibility of breast-conserving treatment (BCT) without surgery.

Published in Journal of Clinical Oncology • May 20, 2018

Authors:

Mark Basik

Joseph P. Costantino

Jennifer F. De Los Santos

Abstract

TPS604 Background: The increased use of neoadjuvant chemotherapy (NCT) has enabled higher rates of breast-conserving surgery (BCS) as well as provided prognostic information for women with breast cancer. High pathological complete response (pCR) rates question the requirement for surgery, with its a...

Subject

Medicine

Breast cancer

Neoadjuvant therapy

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!